Precedex for Schizophrenia

Summary

Precedex for Schizophrenia is a clinical trial^[1].

Key Facts

• Precedex for Schizophrenia is in the country of United States^[2].
• Precedex for Schizophrenia's instance of is recorded as clinical trial^[3].
• Precedex for Schizophrenia's start time is recorded as +2019-11-30T00:00:00Z^[4].
• Precedex for Schizophrenia's end time is recorded as +2020-11-30T00:00:00Z^[5].
• Precedex for Schizophrenia's sponsor is recorded as Yale University^[6].
• Precedex for Schizophrenia's main subject is recorded as schizophrenia^[7].
• Precedex for Schizophrenia's number of participants is recorded as {'unit': '1', 'amount': '+50'}^[8].
• Precedex for Schizophrenia's title is recorded as Safety and Efficacy of Intravenous Dexmedetomidine in the Treatment of Schizophrenia^[9].
• Precedex for Schizophrenia's short name is recorded as DEX^[10].
• Precedex for Schizophrenia's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Precedex for Schizophrenia's ClinicalTrials.gov ID is recorded as NCT03708315^[12].
• Precedex for Schizophrenia's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[13].
• Precedex for Schizophrenia's research intervention is recorded as dexmedetomidine^[14].
• Precedex for Schizophrenia's clinical trial phase is recorded as phase II clinical trial^[15].
• Precedex for Schizophrenia's study type is recorded as interventional study^[16].